OmniAb licenses an antibody discovery platform to drug developers and academic institutions. It last closed at $5.05 on Nov 17, up 3.27% on the day. OABI last reported earnings on Fri, Oct 30, 2026. The average 12-month price target from 2 analysts is $9.00 (+78.2% from the last close), with a high of $12.00 and a low of $6.00. In the past 30 days there were 1 dark pool print totaling $132K, the largest $132K.
Only 2 firms rated OABI in the past 90 days, not enough for a consensus
Average 12-month target
$9.00
▲ 78.2% upside
Based on 2 analysts who set a price target on OABI in the past 90 days. The average target is $9.00, with a high of $12.00 and a low of $6.00, compared with the last close of $5.05.
Low $6.00Avg $9.00High $12.00
Blue marker: last close $5.05
Highest target$12.00
Average target$9.00
Lowest target$6.00
Latest rating changes
Leerink PartnersMaintained
Oct 7Buy$12
StoneXMaintained
Oct 7Buy$6
HC Wainwright & Co.Reiterated
Aug 17Buy$11
Date
Firm
Action
Rating
Price target
Oct 7
Leerink Partners
Maintained
Buy
$12
Oct 7
StoneX
Maintained
Buy
$6
Aug 17
HC Wainwright & Co.
Reiterated
Buy
$11
Loading…
Technical Analysis
OABI · as of the Nov 17 close · updated after every close
Uptrend
The stock is 1% above its 20 day and 6% above its 50 day average. It is 43% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the 20 day average at $5.01, and the nearest resistance the swing high (Oct 2) at $5.09.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.5%/day
Key levels
$5.4552 week high+7.9%
$5.14Pivot R1+1.8%
$5.09Swing high (Oct 2)+0.8%
$5.05Last close
$5.0120 day average−0.8%
$4.98Pivot−1.4%
$4.89Pivot S1−3.2%
$4.79Swing low (Nov 5)−5.1%
$4.7750 day average−5.5%
$3.90100 day average−22.8%
$2.89200 day average−42.8%
$1.3552 week low−73.3%
Indicators
RSI (14)
53.56
Middle of its range
Neutral
MACD
0.08
Below its signal line
Bearish
Stochastic
54.5
Middle of its range
Neutral
ADX (14)
15.3
No clear trend
Williams %R
-36.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
-2.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.9%
Change over 10 sessions
Bearish
ATR (14)
$0.33
Typical daily range, 6.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Turning up, overbought
Short trendBullish
Long trendNeutral
MomentumStrong
StretchOverbought
VolatilityHigh, 11.0%/day
Key levels
$5.4552 week high+7.9%
$5.14Pivot R1+1.8%
$5.09Swing high (Oct 2)+0.8%
$5.05Last close
$5.0120 day average−0.8%
$4.98Pivot−1.4%
$4.89Pivot S1−3.2%
$4.79Swing low (Nov 5)−5.1%
$4.7750 day average−5.5%
$3.90100 day average−22.8%
$2.89200 day average−42.8%
$1.3552 week low−73.3%
Indicators
RSI (14)
71.33
Overbought above 70
Overbought
MACD
0.71
Above its signal line
Bullish
Stochastic
81.2
Near the top of its range
Overbought
ADX (14)
43.2
Strong uptrend
Williams %R
-23.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
66.7
Oversold below −100, overbought above 100
Neutral
Rate of change
+24.1%
Change over 10 sessions
Bullish
ATR (14)
$0.55
Typical daily range, 11.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for OABI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OABI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OABI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OABI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OABI is in one of them and how their past OABI trades turned out.
OmniAb is a discovery research company based in Emeryville, California. It licenses its antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses genetically engineered rats, mice and chickens whose immune systems produce fully human antibody candidates, which are then screened to find those suited to a partner's drug development. Customers use the resulting antibodies in their own therapy programs.